A specialized apheresis procedure that simultaneously removes a patient's defective or pathological red blood cells and replaces them with donor red blood cells. The primary indication is sickle cell disease, where RBCX reduces HbS% while maintaining an appropriate hematocrit without causing iron overload.
Red Blood Cell Exchange uses a continuous-flow apheresis instrument to simultaneously withdraw the patient's red blood cells and replace them with compatible donor packed red blood cells (pRBCs). Unlike simple transfusion, RBCX does not increase total blood volume or iron load, because the patient's own cells are removed at the same rate that donor cells are infused.
The key therapeutic goal in sickle cell disease is reducing the proportion of hemoglobin S (HbS) in the patient's circulating red cell mass. Sickle hemoglobin polymerizes under conditions of hypoxia, acidosis, or dehydration, causing red cells to assume the characteristic sickle shape. Sickled cells are rigid, adhesive, and have a shortened lifespan — they obstruct microvascular flow, trigger vaso-occlusive crises, and cause end-organ damage over time.
By replacing sickle cells with donor HbA cells, RBCX dilutes the HbS fraction below the threshold at which sickling and vaso-occlusion occur. The procedure is isovolemic — the patient's total blood volume and hematocrit are maintained throughout, avoiding the volume overload and iron accumulation associated with chronic simple transfusion programs.
Fraction of Cells Remaining (FCR): FCR is the proportion of the patient's original red cells that remain in circulation after the exchange. FCR = Target HbS% ÷ Starting HbS%. A lower FCR means more of the patient's cells were replaced, resulting in a lower post-procedure HbS%.
Iron Neutrality: Because RBCX removes the patient's iron-containing red cells while replacing them with donor cells, the net iron balance is near zero. This is a major advantage over chronic simple transfusion, which progressively accumulates iron and requires chelation therapy.
Alloimmunization Risk: Repeated exposure to donor red cell antigens can lead to alloantibody formation, complicating future transfusion. Extended antigen matching (C, E, K, Jk, Fy) is recommended for sickle cell patients on chronic RBCX programs to minimize this risk.
The instrument simultaneously removes patient RBCs and replaces them with donor pRBCs in a single continuous phase. The patient's hematocrit is maintained throughout. This is the most common protocol for both acute and chronic indications.
A two-phase protocol. In the first phase, patient RBCs are removed and replaced with saline or albumin (depletion phase), lowering the Hct. In the second phase, donor pRBCs are infused to restore the target Hct. Allows greater HbS% reduction per session.
Patient RBCs are removed and replaced with saline or albumin without donor RBC infusion. Results in a lower Hct. Used in specific clinical scenarios where reducing RBC mass is the primary goal rather than HbS% reduction.
| Condition | Category | Grade | Notes |
|---|---|---|---|
| Sickle Cell Disease — Acute Stroke | I | 1A | Target HbS <30%; reduces stroke recurrence risk |
| Sickle Cell Disease — Stroke Prophylaxis (Chronic) | I | 1B | Monthly RBCX preferred over simple transfusion for iron neutrality |
| Sickle Cell Disease — Acute Chest Syndrome (Severe) | I | 1B | Rapidly reduces HbS%; improves oxygenation |
| Sickle Cell Disease — Preoperative Management | I | 1B | Target HbS <30% before high-risk surgery |
| Sickle Cell Disease — Multiorgan Failure | II | 2C | Adjunct in severe vaso-occlusive crisis with organ involvement |
| Babesiosis — Severe | II | 2C | High parasitemia (>10%), hemolysis, or organ failure |
Donor units must be confirmed HbS-negative to ensure the exchanged cells do not contain sickle hemoglobin. This is a mandatory requirement for all RBCX procedures in sickle cell disease.
For chronic RBCX programs, units should be matched for C, E, and K antigens at minimum. Extended matching for Jk(a), Fy(a), and Fy(b) is recommended to reduce alloimmunization risk in patients receiving repeated transfusions.
All units should be pre-storage leukoreduced to reduce febrile non-hemolytic transfusion reactions, CMV transmission risk, and HLA alloimmunization.
Irradiation is required for immunocompromised patients to prevent transfusion-associated graft-versus-host disease (TA-GvHD). Discuss with the blood bank for each patient's specific requirements.